Register for our free email digests:
Division of Celgene Corp.
Latest From Cilag GMBH International
In Vivo's editors pick June's most significant deals, including Idorsia's IPO and Medtronic's outcomes-based contract with Aetna. (Free article.)
It looks likely AbbVie. and Johnson & Johnson's Imbruvica (ibrutinib) will be made routinely available on the NHS in England and Wales for treating chronic lymphocytic leukemia after an undisclosed price cut was offered and data further considered by the UK HTA NICE.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.
In Vivo's editors pick October's most significant deals, including stealthy Carrick's big Series A and AstraZeneca's out-licensing spree. (Article free with registration.)
- Specialty Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- North America
- Parent & Subsidiaries
- Celgene Corp.
- Senior Management
Patrick J Mahaffy, Pres. & CEO
Erle T Mast, EVP, CFO
Andrew R Allen, PhD, EVP, CMO
- Contact Info
Phone: (720) 564-9100
2525 28th St.
Boulder, CO 80301
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.